ReviewFrontiers in endocrinology2022
Review of the correlation between Chinese medicine and intestinal microbiota on the efficacy of diabetes mellitus.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.Pharmaceutical biology · 2024Pooled it
- Influencing factors for residual kidney function in incident peritoneal dialysis patients: a systematic review and meta-analysis.Renal failure · 2023Pooled it
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
- From "Monarch, Minister, Assistant, and Envoy" to "Microbial Dialogue": A Review of Novel Mechanisms by Which Chinese Herb Pairs Improve Metabolic Diseases Through Gut Microbiota Metabolic Regulation.Gastroenterology research and practice · 2026Review
- Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation.Chemistry & biodiversity · 2026Article
- Review
- Article
- Article
- Crosstalk Between Bile Acids and Intestinal Epithelium: Multidimensional Roles of Farnesoid X Receptor and Takeda G Protein Receptor 5.International journal of molecular sciences · 2025Review
- Exploration of the mechanisms of HLWDD on skeletal muscle lesions under the influence of diabetes based on bioinformatics analysis and experimental validation.Frontiers in nutrition · 2025Article
- Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review.Frontiers in immunology · 2025Review
- 5-deoxy-rutaecarpine protects against LPS-induced acute lung injury via inhibiting NLRP3 inflammasome-related inflammation.Frontiers in pharmacology · 2025Article
- Correlation between serum 25(OH)D levels and diabetic foot ulcers in elderly patients with type 2 diabetes mellitus.American journal of translational research · 2025Article
- Analysis of immune cell activation in patients with diabetes foot ulcer from the perspective of single cell.European journal of medical research · 2024Article
- Theoretical Study of Gas Sensing toward Acetone by a Single-Atom Transition Metal (Sc, Ti, V, and Cr)-Doped InPACS omega · 2024Article
- Synthesis and biological evaluation of diclofenac acid derivatives as potential lipoxygenase and α-glucosidase inhibitors.Royal Society open science · 2024Article
- Anti-Oxidative and Anti-Apoptotic Oligosaccharides fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Double resolvability parameters of fosmidomycin anti-malaria drug and exchange property.Heliyon · 2024Article
- Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors.Future medicinal chemistry · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a serious metabolic disorder that can lead to a number of life-threatening complications. Studies have shown that intestinal microbiota is closely related to the development of diabetes, making it a potential target for the treatment of diabetes. In recent years, research on the active ingredients of traditional Chinese medicine (TCM), TCM compounds, and prepared Chinese medicines to regulate intestinal microbiota and improve the symptoms of diabetes mellitus is very extensive. We focus on the research progress of TCM active ingredients, herbal compounds, and prepared Chinese medicines in the treatment of diabetes mellitus in this paper. When diabetes occurs, changes in the abundance and function of the intestinal microbiota disrupt the intestinal environment by disrupting the intestinal barrier and fermentation. TCM and its components can increase the abundance of beneficial bacteria while decreasing the abundance of harmful bacteria, regulate the concentration of microbial metabolites, improve insulin sensitivity, regulate lipid metabolism and blood glucose, and reduce inflammation. TCM can be converted into active substances with pharmacological effects by intestinal microbiota, and these active substances can reverse intestinal microecological disorders and improve diabetes symptoms. This can be used as a reference for diabetes prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.